Algeta to present new clinical data from three phase II trials with
Alpharadin at ECCO 15 - 34th ESM
(Thomson Reuters ONE) - Oslo, Norway, 17 September 2009 - Algeta ASA (OSE: ALGETA), thecancer therapeutics company, announces that new clinical data fromthree phase II clinical trials with Alpharadin comprising its phaseII efficacy and safety program will be presented at the joint 15thCongress of the European CanCer Organisation (ECCO) and 34th Congressof the European Society for Medical Oncology (ESMO). The congresswill take place in the Internationale Congress Centrum Berlin,Berlin, Germany from 20-24 September 2009.Alpharadin is Algeta's lead cancer therapeutic and has recently beenpartnered with Bayer. It is the first in a new class ofalpha-emitting pharmaceuticals ('alpha-pharmaceutical') and is basedon radium-223. Alpharadin is in a global phase III clinical trial(ALSYMPCA) designed to confirm its efficacy and safety as a targetedtreatment for bone metastases in men with hormone-refractory prostatecancer (HRPC). Alpharadin is administered as a simple injection andhas a unique mode of action whereby it targets bone metastasesspecifically and exerts a highly localized effect on tumor cellswhile minimizing damage to normal surrounding tissues. In phase IIstudies previously reported, Alpharadin demonstrated strong evidencethat it can prolong patient survival, improve quality of life andoffer a benign safety profile.Data from the three phase II trials being reported at ECCO are:BC1-02 - Two-year follow-up data from a 64-patient efficacy andsafety study evaluating survival and long-term toxicity in men withbone metastases resulting from HRPC following treatment withAlpharadin.A poster (Abstract No. 7.018) will be presented by Prof. OyvindBruland (Norwegian Radium Hospital, Oslo, Norway).Date /Time: 22 September 2009, from 09:00 to 12:00 hrsSession: "Genitourinary malignancies - Prostate cancer"Location: Exhibition Hall 14.1 (Poster Board 215)BC1-03 - Final results from a 100-patient study investigating thepain-relieving effects and dose-response relationship after a singledose of Alpharadin.A poster (Abstract No. 7.011) will be presented by Prof. Sten Nilsson(Karolinska Hospital, Stockholm, Sweden).Date /Time: 22 September 2009, from 09:00 to 12:00 hrsSession: "Genitourinary malignancies - Prostate cancer"Location: Exhibition Hall 14.1 (Poster Board 208)BC1-04 - Final results from a 122-patient efficacy and safety studydesigned to compare the prostate cancer specific antigen (PSA)response rate of three different repeat doses of Alpharadin.An oral presentation (Abstract No 7.003) will be given by Dr. ChrisParker (Institute of Cancer Research and Royal Marsden Hospital,Sutton, UK), who is principal investigator of the ALSYMPCA phase IIIstudy.Date/time: 21 September 2009, 11.45-12.00 hrsSession: Proferred Paper Session: "Genitourinary malignancies -Prostate cancer"Location: Hall 3 ###For further information, please contactFor AlgetaAndrew Kay, CEO +47 2300 6742 / +47 4840 1360 (mob)Gillies O'Bryan-Tear, CMO +47 23 00 7824 / +44 7971 986 813 (mob)Thomas Ramdahl, EVP & CTO +47 23 00 7990 / +47 913 91 458 (mob) post(at)algeta.comCitigate Dewe Rogerson +44 (0) 207 638 9571Mark Swallow / Helena Galilee mark.swallow(at)citigatedr.co.uk/ David DibleAbout AlgetaAlgeta ASA is a cancer therapeutics company built on world-leading,proprietary technology. Algeta is developing a new generation oftargeted cancer therapeutics (alpha-pharmaceuticals) that harness theunique characteristics of alpha particle emitters and are potent,well-tolerated and convenient to use.Algeta's lead alpha-pharmaceutical candidate, Alpharadin (based onradium-223), has blockbuster potential for treating bone metastasesarising from multiple major cancer types, owing to its bone-targetingnature, potent efficacy (therapeutic and palliative) and benign,placebo-like safety profile. Development of Alpharadin is mostadvanced targeting bone metastases resulting from hormone-refractoryprostate cancer (HRPC), and it entered an international phase IIIclinical trial (ALSYMPCA) in mid-2008 based on compelling clinicalresults from a comprehensive phase II program. This trial iscurrently open for recruitment.In September 2009, Algeta entered into an global agreement with BayerHealthcare AG for the development and commercialization ofAlpharadin. As part of the agreement, Algeta retains an option toco-promote Alpharadin in the United States and to share profits fromfuture sales.Algeta is also developing other technologies for deliveringalpha-pharmaceuticals. These include methods to enhance the potencyof therapeutic antibodies and other tumor-targeting molecules bylinking them to the alpha particle emitter thorium-227. The Companyis headquartered in Oslo, Norway, and was founded in 1997. Algetalisted on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).Alpharadin and Algeta are trademarks of Algeta ASA.Forward-looking StatementThis news release contains forward-looking statements and forecastsbased on uncertainty, since they relate to events and depend oncircumstances that will occur in the future and which, by theirnature, will have an impact on results of operations and thefinancial condition of Algeta. There are a number of factors thatcould cause actual results and developments to differ materially fromthose expressed or implied by these forward-looking statements.Theses factors include, among other things, risks associated withtechnological development, the risk that research & development willnot yield new products that achieve commercial success, the impact ofcompetition, the ability to close viable and profitable businessdeals, the risk of non-approval of patents not yet granted anddifficulties of obtaining relevant governmental approvals for newproducts. ###http://hugin.info/134655/R/1341743/321002.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.09.2009 - 02:31 Uhr
Sprache: Deutsch
News-ID 1004374
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 158 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta to present new clinical data from three phase II trials with
Alpharadin at ECCO 15 - 34th ESM
"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
